| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d99e27b25e8a30a7f4196fb2df70efee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5096615470e3bcea8ee2341fd8390eef |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C251-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C255-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C253-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C253-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2013-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79b759da372bc1b81bc2120e6e885827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79ff95835f4bb9e1dcbcb68b8415c941
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dde408161a3a47d3464c577bac158074
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35821796e7b7b1bc73cd176b0ace9270 |
| publicationDate |
2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016023996-A1 |
| titleOfInvention |
Cancer Chemotherapeutic Agent/Formulation, Manufacture and Use Thereof |
| abstract |
A cancer chemotherapeutic agent that is particularly kinase suppressing and/or any other signaling pathway interfering agents and pharmaceutical formulations/compositions involving the same and its process of manufacture is provided. A potential the cancer chemotherapeutic agent is provided which apart from stated anticancer activity as a proven kinase suppressing and/or any other signaling pathway interfering agent could also involve specific potential binding affinity towards the intramolecular G-Quadruplex DNA structure and/or other potential quadruplex forming sequences over duplex DNA structures favours further diverse end use and application including but not limited to antiaging, antiangiogenic, antiproliferative, antitumor, antibiotic, antiviral, antifungal and multiple anticancer therapeutics, and also possesses favourable cytotoxicity values towards uncontrollably proliferative cells by inducing apoptosis irrespective of cells' p53 status, without being cytotoxic to normal cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019100746-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745529-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106831485-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109153991-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109153991-B |
| priorityDate |
2012-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |